Following early positive signals of benefit from the immune modulation therapy domain of the REMAP-CAP platform trial, a UK wide position statement has been agreed to support off-label prescribing and access to tocilizumab, administered intravenously, for eligible COVID positive patients in the intensive care setting.

Tocilizumab (RoActemra®) a humanised monoclonal antibody against the interleukin-6 (IL-6) receptor.
The advice is that Tocilizumab should be administered as an intravenous infusion at a dose of 8mg per kg, up to a maximum dose of 800mg. A second infusion may be given after 12-24 hours if after the initial dose there has not been sufficient clinical improvement.
Cambridge Life Sciences Ltd are the exclusive distributor in the UK for the LisaTracker Tocilizumab and LisaTracker Anti-Tocilizumab manufactured by Theradiag for monitoring levels in patient sera.
For more information, contact

Mar 2020